產(chǎn)品詳情
簡(jiǎn)單介紹：
重組人胰島素樣生長(zhǎng)因子結(jié)合蛋白3蛋白與其它公司提供的重組蛋白不同，rHuIGF-BP3蛋白產(chǎn)品為采用CFS的無(wú)細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來(lái)的重組蛋白，可表達(dá)出對(duì)細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡(jiǎn)便高效，將蛋白純化過(guò)程中對(duì)蛋白的損傷降低到*小程度.重組人胰島素樣生長(zhǎng)因子結(jié)合蛋白3蛋白（全長(zhǎng)序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測(cè)、ELISA等試驗(yàn)中.
詳情介紹：
重組人胰島素樣生長(zhǎng)因子結(jié)合蛋白3蛋白
| Synonyms | Growth-hormone-dependant Binding Protein, IBP-3, IGF-binding protein 3 |
| Species | Human |
| Accession | P17936 |
| GeneID | 3486 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人胰島素樣生長(zhǎng)因子結(jié)合蛋白3蛋白Approximately 28.8 kDa, a single non-glycosylated polypeptide chain containing 264 amino acids. |
| Quantity | 5μg/25μg/1000μg |
| AA Sequence | GASSGGLGPV VRCEPCDARA LAQCAPPPAV CAELVREPGC GCCLTCALSE GQPCGIYTER CGSGLRCQPS PDEARPLQAL LDGRGLCVNA SAVSRLRAYL LPAPPAPGNA SESEEDRSAG EVESPSVSST HRVSDPKFHP LHSKIIIIKK GHAKDSQRYK VDYESQSTDT QNFSSESKRE TEYGPCRREM EDTLNHLKFL NVLSPRGVHI PNCDKKGFYK KKQCRPSKGR KRGFCWCVDK YGQPLPGYTT KGKEDVHCYS MQSK |
| Purity | > 98 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人胰島素樣生長(zhǎng)因子結(jié)合蛋白3蛋白Fully biologically active when compared to standard. The ED50 as determined by inhibiting IGF-II induced proliferation of serum free human MCF-7 cells is less than 200 ng/ml, corresponding to a specific activity of > 5.0 × 103 IU/mg in the presence of 15 ng/ml of rHuIGF-II. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | 重組人胰島素樣生長(zhǎng)因子結(jié)合蛋白3蛋白Less than 1 EU/μg of rHuIGF-BP3 as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人胰島素樣生長(zhǎng)因子結(jié)合蛋白3蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Grellier P, Sabbah M, Fouqueray B, et al. 1996. Kidney Int, 49: 1071-8. 2. Yilmaz MD, Hosal AS, Oguz H, et al. 2002. Laryngoscope, 112: 922-5. 3. Deming SL, Ren Z, Wen W, et al. 2007. Breast Cancer Res Treat, 104: 309-19. 4. Satterfield MC, Hayashi K, Song G, et al. 2008. Biol Reprod, 79: 1226-36. 5. Key TJ, Appleby PN, Reeves GK, et al. 2010. Lancet Oncol, 11: 530-42. |
| Background | Insulin-like Growth Factor-Binding Protein 3 (IGF-BP3) belongs to the IGFBP family, which are all cysteinerich proteins with conserved cysteine and have an IGFBP domain and a thyroglobulin type-I domain. Mature human IGF-BP3 contains 264 a.a. with three potential N-linked and two potential O-linked glycosylation sites. It is expressed by most tissues and has higher levels during extrauterine life and peak during puberty. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. The protein forms a ternary complex with IGF-I or II and acid-labile subunit. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Decreased plasma levels of IGF-BP3 often happen during the progression of prostate cancer from benign to metastatic disease. |
